This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
All content for Condensed IP is the property of Randy Noranbrock and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
Apex Bank v. CC Serve (Fed. Cir., September 25, 2025) 2023-2143
Condensed IP
12 minutes
1 month ago
Apex Bank v. CC Serve (Fed. Cir., September 25, 2025) 2023-2143
This episode concerns a decision from the United States Court of Appeals for the Federal Circuit. The court opinion, Apex Bank v. CC Serve Corp., decided on September 25, 2025, addresses an appeal from the Trademark Trial and Appeal Board regarding the likelihood of confusion between the ASPIRE mark used by CC Serve and the proposed ASPIRE BANK marks of Apex Bank. The Federal Circuit affirmed-in-part, vacated-in-part, and remanded the case, specifically upholding the Board's finding of high s...
Condensed IP
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
